An orthotopic model of human pancreatic cancer in severe combined immunodeficient mice: Potential application for preclinical studies

Clinical Cancer Research

Volumn 4, Issue 4, 1998, Pages 887-894

  Mohammad, Ramzi M ^a   Al Katib, Ayad ^a   Pettit, George R ^b   Vaitkevicius, Vainutis K ^a   Joshi, Urwashi ^a   Adsay, Volkan ^a   Majumdar, Adhip P N ^a   Sarkar, Fazlul H ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b ARIZONA STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AURISTATIN PE; DOLASTATIN 10; GEMCITABINE; PROTEIN P21; PROTEIN P53; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER TRANSPLANTATION; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; NONHUMAN; PANCREAS ADENOCARCINOMA; PANCREAS CANCER; PRIORITY JOURNAL; SCID MOUSE;

ADENOCARCINOMA; ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DEOXYCYTIDINE; DISEASE MODELS, ANIMAL; FEMALE; MICE; MICE, INBRED ICR; MICE, SCID; OLIGOPEPTIDES; PANCREATIC NEOPLASMS; TRANSPLANTATION, HETEROLOGOUS;

EID: 0031943257     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Parker, S. L., Tong, T., Bolen, S., and Wingo, P. A. Cancer statistics. CA Cancer J. Clin., 47: 5-27, 1997.
2. Gudjonnson, B. Carcinoma of the pancreas: 50 years of surgery. Cancer (Phila.), 60: 2284-2303, 1987.
3. Warshaw, A. W., and Fernandez-del Castillo, C. Pancreatic carcinoma. N. Engl. J. Med., 326: 455-465, 1992.
4. Lillemore, K. D. Current management of pancreatic carcinoma. Ann. Surg., 221: 133-148, 1995.
5. Casper, E. S., and Kelson, D. P. Adenocarcinoma of the pancreas: overview of workup and management. Adv. Oncol., 11: 17-22, 1995.
6. Kelly, D. M., and Benjamin, I. S. Pancreatic carcinoma. Ann Oncol., 6: 19-28, 1995.
7. Hertel, L. W., Boder, G. B., Kroin, J. S., Rinzel, S. M., Poore, G. A., and Todd, G. C. Evaluation of the anti-tumor activity of gemcitabine (2′,2′-difluoro-2′-deoxycytidine). Cancer Res., 50: 4417-4422, 1990.
8. Grindey, G. B., Hertel, L. W., and Plunkett, W. Cytotoxicity and anti-tumor activity of 2′,2′-difluoro-2′-deoxycytidine (gemcitabine). Cancer Invest., 8: 313-318, 1990.
9. Rothenberg, M. L., Moore, M. J., Cripps, M. C., et al. A Phase II trial of gemcitabine in patients with 5-FU-refractory pancreas cancer. Ann. Oncol., 7: 347-353, 1996.
10. Pettit, G. R., Kamano, Y., Herald, C. L., Tuinman, A. A., Boettner, F. E., Kizu, H., Schmidt, J. M., Baczynskyj, L., Tomer, K. B., and Bontems, R. J. The isolation and structure of a remarkable marine animal antineoplastic constituent: dolastatin 10. J. Am. Chem. Soc., 109: 6883-6894, 1987.
11. Pettit, G. R. The dolastatins. In: W. Herz, G. W. Kirby, R. E. Moore, W. Steglich, and C. Tamm (eds.), Progress in the Chemistry of Organic Natural Products, pp. 2-63. New York: Springer, 1997.
12. Bai, R., Roach, M. C., Jayaram, S. K., Barkoczy, J., Pettit, G. R., Luduena, R. F., and Hamel, E. Differential effects of active isomers, segments, and analogs of dolastatin 10 on ligand interactions with tubulin. Correlation with cytotoxicity. Biochem. Pharmacol., 45: 1503-1515, 1993.
13. Pettit, G. R., Srirangam, J. K., Barkoczy, J., Williams, M. D., Durkin, K. P., Boyd, M. R., Bai, R., Hamel, E., Schmidt, J. M., and Chapuis, J. C. Antineoplastic agents 337. Synthesis of dolastatin 10 structural modifications. Anti-Cancer Drug Design, 10: 529-544, 1995.
14. Fogh, J., Orfeo, T., Tiso, J., Sharkey, F. E., Fogh, J. M., and Daniels, W. P. Twenty-three new human tumor lines established in nude mice. Exp. Cell Biol., 48: 229-239, 1980.
15. Sordat, B. C., Ueyama, Y., and Fogh, J. Metastasis of tumor xenografts in the nude mouse. In: J. Fogh and B. C. Giovanella (eds.), The Nude Mouse in Experimental and Clinical Research, Vol. 2, pp. 95-143. New York: Academic Press, 1982.
16. Vezeridis, M. P., Doremus, C. M., Tibbetts, L. M., Tznnakakis, G., and Jackson, B. T. Invasion and metastasis following orthotopic transplantation of human pancreatic cancer in the nude mouse. J. Surg. Oncol., 40: 261-265, 1989.
17. Marincola, F. M., Drucker, B. J., Siao, B. Y., Hough, K. L., and Holder, W. D. The nude mouse as a model for the study of human pancreatic cancer. J. Surg. Res., 47: 520-529, 1989.
18. Tan, M. H., and Chu, T. M. Characterization of the tumorigenic and metastatic properties of a human pancreatic tumor cell line (AsPc-1) implanted orthotopically into nude mice. Tumor Biol., 6: 89-98, 1985.
19. Fu, X., Guadagni, F., and Hoffman, R. M. A metastatic nude-mouse model of human pancreatic cancer constructed orthotopically with histologically intact patient specimens. Proc. Natl. Acad. Sci. USA, 89: 5645-5649, 1992.
20. Reyes, G., Villanueva, A., Garcia, C., Sancho, S. J., Piulats, J., Liuis, F., and Capella, G. Orthotopic xenografts of human pancreatic carcinomas acquire genetic aberrations during dissemination in nude mice. Cancer Res., 56: 5713-5719, 1996.
21. waf1 recombinant adenovirus. Pancreas, in press, 1998.
22. Mohammad, R. M., Dugan, M. C., Mohamed, A. N., Almatchy, V. P., Flake, T. M., Dergham, S. T., Shields, A. F., Al-Katib, A. M., Vaitkevicius, V. K., and Sarkar, F. H. Establishment of human pancreatic tumor xenograft model: potential application for preclinical evaluation of novel therapeutic agents. Pancreas, 16: 19-25, 1998.
23. WAF-1 and p53 expression in pancreatic adenocarcinoma. Cancer, 80: 372-381, 1997.
24. Bai, R., Pettit, G. R., and Hamel, E. Dolastatin 10, a powerful cytostatic peptide derived from a marine animal. Inhibition of tubulin polymerization mediated through the Vinca alkaloid binding domain. Biochem. Pharmacol., 39: 1941-1949, 1990.
25. Luduena, R. F., Roach, M. C., Prasad, V., and Pettit, G. R. Interaction of dolastatin 10 with bovine brain tubulin. Biochem. Pharmacol., 43: 539-543, 1992.